Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach

被引：6

作者：

Fontanella, Caterina ^{[1
]}

Giorgi, Carlo Alberto ^{[2
]}

Russo, Stefania ^{[3
]}

Angelini, Silvia ^{[4
]}

Nicolardi, Linda ^{[5
]}

Giarratano, Tommaso ^{[2
]}

Frezzini, Simona ^{[2
]}

Pestrin, Marta ^{[6
]}

Palleschi, Dario ^{[4
]}

Bolzonello, Silvia ^{[7
]}

Parolin, Veronica ^{[8
]}

Haspinger, Eva R. ^{[9
]}

De Rossi, Costanza ^{[10
]}

Greco, Filippo ^{[11
]}

Gerratana, Lorenzo ^{[7
,12
]}

机构：

[1] Osped San Martino, ULSS1 Dolomiti Veneto, Med Oncol, Belluno, Italy

[2] IRCCS, Ist Oncol Veneto IOV, Med Oncol 2, Padua, Italy

[3] ASU FC Univ Hosp, Dept Oncol, Udine, Italy

[4] Azienda ULSS 2 Marca Trevigiana, Med Oncol Unit, Treviso, Italy

[5] Ospedali Riuniti Padova Sud Immacolata Concez, Med Oncol, Piove Di Sacco, PD, Italy

[6] Azienda Sanit Univ Giuliano Isontina, Med Oncol, Gorizia, Italy

[7] IRCCS, Ctr Riferimento Oncol Aviano CRO, Dept Med Oncol, Aviano, PN, Italy

[8] Univ Verona, Dept Med, Sect Oncol, Azienda Osped Univ Integrata Verona, Verona, Italy

[9] Merano Hosp, Azienda Osped Alto Adige, Med Oncol, Merano, BZ, Italy

[10] Osped Angelo, Med Oncol, ULSS3 Serenissima, Mestre Venezia, Italy

[11] Mater Salutis Hosp, Dept Oncol, ULSS9, Verona, Italy

[12] IRCCS, Ctr Riferimento Oncol CRO, Dept Med Oncol, Aviano, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 180卷

关键词：

CDK4; 6; inhibitor; Advanced breast cancer; HR-positive; HER2-negative; Biomarkers; Personalized medicine; ADVANCED BREAST-CANCER; CIRCULATING TUMOR DNA; FULVESTRANT; 500; MG; ANASTROZOLE; QUALITY-OF-LIFE; RIBOCICLIB PLUS LETROZOLE; THYMIDINE KINASE-ACTIVITY; ENDOCRINE THERAPY; 1ST-LINE TREATMENT; DRUG-INTERACTIONS;

D O I：

10.1016/j.critrevonc.2022.103848

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are now a backbone of treatment for hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. CDK4/6i plus ET is more effective than ET alone in this setting; however, the risk of grade 3-4 adverse events also increases. Approved agents in this class have similar efficacies, but important differences due to their structural and pharmacological properties. We review biomarkers and discuss determinants to inform a rational approach to therapy choice when selecting the most appropriate ET and CDK4/6i partners. We also identify subgroups that may benefit from specific ET-CDK4/6i combinations and discuss strategies to overcome resistance. This personalized approach aims to minimize treatment-related toxicities that may affect patient QoL and compliance, and ultimately therapy efficacy.

引用

页数：12

共 105 条

[1] Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1 [J].

Andre, F. ;

Ciruelos, E. M. ;

Juric, D. ;

Loibl, S. ;

Campone, M. ;

Mayer, I. A. ;

Rubovszky, G. ;

Yamashita, T. ;

Kaufman, B. ;

Lu, Y-S ;

Inoue, K. ;

Papai, Z. ;

Takahashi, M. ;

Ghaznawi, F. ;

Mills, D. ;

Kaper, M. ;

Miller, M. ;

Conte, P. F. ;

Iwata, H. ;

Rugo, H. S. .

ANNALS OF ONCOLOGY, 2021, 32 (02) :208-217

[2]

Andre F, 2020, J CLIN ONCOL, V38

[3] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].

Andre, Fabrice ;

Ciruelos, Eva ;

Rubovszky, Gabor ;

Campone, Mario ;

Loibl, Sibylle ;

Rugo, Hope S. ;

Iwata, Hiroji ;

Conte, Pierfranco ;

Mayer, Ingrid A. ;

Kaufman, Bella ;

Yamashita, Toshinari ;

Lu, Yen-Shen ;

Inoue, Kenichi ;

Takahashi, Masato ;

Papai, Zsuzsanna ;

Longin, Anne-Sophie ;

Mills, David ;

Wilke, Celine ;

Hirawat, Samit ;

Juric, Dejan .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940

[4] Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib [J].

Bardia, Aditya ;

Su, Fei ;

Solovieff, Nadia ;

Im, Seock-Ah ;

Sohn, Joohyuk ;

Lee, Keun Seok ;

Campos-Gomez, Saul ;

Jung, Kyung Hae ;

Colleoni, Marco ;

Villanueva Vazquez, Rafael ;

Franke, Fabio ;

Hurvitz, Sara ;

Harbeck, Nadia ;

Chow, Louis ;

Taran, Tetiana ;

Lorenc, Karen Rodriguez ;

Babbar, Naveen ;

Tripathy, Debu ;

Lu, Yen-Shen .

JCO PRECISION ONCOLOGY, 2021, 5 :1408-1420

[5]

Barin S., 2022, ENG SCI TECHNOL INT, V34, P101174, DOI [10.3390/biophysica2030025, 10.1016/j.jestch.2022.101174]

[6] Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper [J].

Battisti, Nicolo Matteo Luca ;

De Glas, Nienke ;

Sedrak, Mina S. ;

Loh, Kah Poh ;

Liposits, Gabor ;

Soto-Perez-de-Celis, Enrique ;

Krok-Schoen, Jessica L. ;

Menjak, Ines B. ;

Ring, Alistair .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10

[7] Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1 [J].

Berger, Frederique ;

Marce, Margaux ;

Delaloge, Suzette ;

Hardy-Bessard, Anne-Claire ;

Bachelot, Thomas ;

Bieche, Ivan ;

Pradines, Anne ;

Rouge, Thibault De La Motte ;

Canon, Jean-Luc ;

Andre, Fabrice ;

Arnould, Laurent ;

Clatot, Florian ;

Lemonnier, Jerome ;

Marques, Sandrine ;

Bidard, Francois-Clement .

BMJ OPEN, 2022, 12 (03)

[8]

Bidard FC, 2020, J CLIN ONCOL, V38

[9]

Bonechi Martina, 2018, Oncotarget, V9, P16389, DOI 10.18632/oncotarget.24700

[10] Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences [J].

Braal, C. Louwrens ;

Jongbloed, Elisabeth M. ;

Wilting, Saskia M. ;

Mathijssen, Ron H. J. ;

Koolen, Stijn L. W. ;

Jager, Agnes .

DRUGS, 2021, 81 (03) :317-331

← 1 2 3 4 5 6 7 8 9 10 →